Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.
Also called NCT03718559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,040 participants
- Registry
-
NCT03718559
-
- Other papers using this trial's data
- Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
- Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
- Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial
- Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial
- Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03718559. Randomized; no masking; primary purpose treatment. Start 2019-05-14 (actual); primary completion 2023-11-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
- Acronym
- EPIC-CAD
- Condition
- Atrial Fibrillation
- Condition
- Coronary Artery Disease
- Condition
- Stable Angina
- Condition
- Stable Chronic Angina
- Intervention (Drug)
- Edoxaban Monotherapy
- Intervention (Drug)
- Edoxaban plus Single Antiplatelet Agent
- Lead sponsor
- Gi-Byoung Nam
- Collaborator
- CardioVascular Research Foundation, Korea
Record details
- Record id
cardio:ct-nct03718559- Content hash
2deba71b9b314a7e309832adbccbd67fdf98d934c2bbc2dcd10e81d1136ae007